MRNA
EquityModerna, Inc.
Health Care · Biotechnology
$55.85
+55.85 (+0.00%)
Open
N/A
Day Range
$51.69 - $56.60
52W Range
$22.28 - $56.60
Volume
11M
Price History
Key Statistics
Market Cap
N/A
P/E Ratio
N/A
EPS
N/A
Dividend Yield
N/A
P/B Ratio
N/A
Payout Ratio
N/A
ROE
N/A
Debt/Equity
N/A
Latest News
Moderna will pay up to $2.25B to end COVID vaccine patent fight
AI in Pharma Manufacturing Market Research 2026-2040: Pfizer, Moderna, Novartis, Merck, and Sanofi are Integrating AI Into Their Operations As the Sector Evolves Towards Pharma 4.0
Moderna’s EU Backing For Combo Vaccine Shifts Respiratory Growth Focus
Rothschild & Co Redburn Adjusts Price Target on Moderna to $40 From $36, Maintains Neutral Rating
Moderna Says It Received Positive EU Panel Opinion for Flu-COVID Combination Vaccine
Peers in Health Care
| Symbol | Name | Price | Mkt Cap | Div Yield | Change |
|---|---|---|---|---|---|
| 001540.KQ | AHN-GOOK PHA | $7,280.00 | N/A | 6.04% | +0.00% |
| A | Agilent Technologies, Inc. | $120.24 | N/A | 0.83% | +0.00% |
| ABUS | Arbutus Biopharma Corporation | $4.60 | N/A | - | +0.00% |
| CRSP | CRISPR Therapeutics AG | $59.95 | N/A | - | +0.00% |
| ABBV | AbbVie Inc. | $234.67 | N/A | 2.83% | +0.00% |
| ABCL | AbCellera Biologics Inc. | $3.65 | N/A | - | +0.00% |
| AKBA | Akebia Therapeutics, Inc. | $1.26 | N/A | - | +0.00% |
| ACAD | ACADIA Pharmaceuticals Inc. | $23.06 | N/A | - | +0.00% |
About Moderna, Inc.
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
www.modernatx.com →Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Borderline
Based on 4 fundamental factors
Analysis Tools
Share
No dividend data available for MRNA
Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Borderline
Based on 4 fundamental factors
Loading financial data...
Revenue & Earnings
No financial statement data available for MRNA.